Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06331845

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma Clinical Trial

Official title:
Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial

Clinical Trial Summary

This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).

Clinical Trial Description

Widely metastatic nasopharyngeal carcinoma (wmNPC) represented a particular subgroup of patients with the worst prognosis, of which palliative systematic chemotherapy(SC) was recommended as initial treatment, however, palliative systematic treatment was often required to be stopped due to the cumulative toxicities while stopping SC may lead to disease progression, a 'stop and go' approach, namely chemotherapy 'holidays', was a new strategy which may keep a good balance of benefit and risk. This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in wmNPC patients who achieve objective response after SC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06331845
Study type Interventional
Source Fujian Cancer Hospital
Contact Shaojun Lin, DR
Phone 13860603879
Email linshaojun@yeah.net
Status Not yet recruiting
Phase Phase 2
Start date May 1, 2024
Completion date May 1, 2028
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05484375 - Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment Phase 2
Not yet recruiting NCT06010095 - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Phase 2
Recruiting NCT03639467 - Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma Phase 1/Phase 2
Recruiting NCT06029270 - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase 2
Active, not recruiting NCT04586088 - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Phase 2
Active, not recruiting NCT04405622 - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 2
Active, not recruiting NCT04872582 - Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study Phase 2
Completed NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Phase 2
Terminated NCT04458909 - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Phase 3
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2
Recruiting NCT04627961 - A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2